This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/genbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/uniprotkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/wikipedia/
n19http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://www.rxlist.com/cgi/generic/
n12http://linked.opendata.cz/resource/drugbank/patent/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/drugbank/
n24http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n4http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00072/identifier/national-drug-code-directory/
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00072
rdf:type
n5:Drug
n5:description
A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*
n5:dosage
n16:271B4364-363D-11E5-9242-09173F13E4C5 n16:271B4363-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11329054 # Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14528282 # Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP: Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004 Feb;57(2):86-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14750129 # Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-68. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12908564 # Tan AR, Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14613027 # IGMT "Link":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=7637 # IGMT "Link":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1N8Z # Nebija D, Kopelent-Frank H, Urban E, Noe CR, Lachmann B: Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. J Pharm Biomed Anal. 2011 Dec 5;56(4):684-91. doi: 10.1016/j.jpba.2011.07.006. Epub 2011 Jul 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21813259 #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995.Trastuzumab; [updated 2014 Nov 05; cited 2014 Nov 12.Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=2&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=233586
n5:group
approved investigational
n5:halfLife
average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.
n5:indication
For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
owl:sameAs
n11:DB00072 n19:DB00072
dcterms:title
Trastuzumab
adms:identifier
n7:Trastuzumab n13:J00228 n14:DB00072 n15:P01857 n17:50242-134-68 n18:PA451743
n5:mechanismOfAction
Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
n5:packager
n23:271B435F-363D-11E5-9242-09173F13E4C5 n23:271B4360-363D-11E5-9242-09173F13E4C5 n23:271B435E-363D-11E5-9242-09173F13E4C5
n5:patent
n12:2103059
n5:synonym
Anti HER2 Ig gamma-1 chain C region
n5:toxicity
Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.
n5:volumeOfDistribution
* 44 mL/kg
n24:hasConcept
n25:M0291428
foaf:page
n4:trastuzumab.html n22:trastuz.htm
n5:Molecular-Formula
n9:271B4369-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n9:271B4368-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:L01XC03
n5:absorption
Peak and trough plasma concentrations at steady state (between weeks 16 and 32) approximately 123 and 79 mcg/mL, respectively.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
180288-69-1
n5:category
n5:clearance
Elimination may involve clearance of IgG through the reticuloendothelial system.
n5:containedIn
n8:271B4362-363D-11E5-9242-09173F13E4C5 n8:271B4361-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n9:271B4366-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n9:271B4367-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n9:271B4365-363D-11E5-9242-09173F13E4C5